Decoy Therapeutics Inc.

Listed Company

DCOYCIK 0001615219NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-12.52M

Total Assets

—

Equity

—

Shares Out

532.0K

Op. Cash Flow

$-4.83M

Business

Salarius Pharmaceuticals, Inc. discovers and develops novel oncology therapeutics that use epigenetic enzymes to modulate transcription factors and control abnormal protein expression. Its main offerings are preclinical and clinical-stage product candidates in oncology, including programs with FDA fast track and breakthrough therapy interactions. Key activities are research and development, clinical trials, regulatory interactions, and licensing of intellectual property and collaborations. Salarius pursues regulatory approvals from agencies such as the U.S. Food and Drug Administration and relies on government funding and strategic partnerships to advance and potentially commercialize its candidates.

Summary from filing dated 2025-03-21

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Acquired in-process research and development	9	0	—	—	—
Research and development	368,170	770,027	7	16	9
General and administrative	4	5	6	7	6
Total operating expenses	13	6	13	32	15
Loss from operations	−13	−6	−13	−32	−13
Interest income and other, net	95,472	158,539	352,251	218,730	—
Net loss	−13	−6	−13	−32	−13
Loss attributable to common stockholders	−13	−6	—	—	—
Net loss per share attributable to common stockholders - basic	−129.1	−69.54	—	—	—
Net loss per share attributable to common stockholders - diluted	−129.1	−69.54	—	—	—
Total net loss per share - basic	−129.1	−69.54	−30.74	−14.88	−7.72
Total net loss per share - diluted	−129.1	−69.54	−30.74	−14.88	−7.72
Weighted-average number of common shares used in net loss per share attributable to common stockholders - basic	96,967	80,184	408,078	2	2
Weighted-average number of common shares used in net loss per share attributable to common stockholders - diluted	96,967	80,184	408,078	2	2

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash, cash equivalents, and restricted cash	11	2	6	12	29
Prepaid expenses and other current assets	275,223	553,034	619,763	803,373	949,215
Total current assets	11	3	7	15	30
Property and equipment, net	40,559	0	—	—	7,880
Other assets	30,988	35,412	66,850	130,501	193,874
Total assets	11	3	7	15	41
Accounts payable	940,586	936,994	602,853	3	2
Accrued expenses and other current liabilities	859,442	352,419	406,745	1	567,787
Deferred revenue	3	0	—	—	—
Notes payable	0	200,000	300,000	0	0
Due to related party	139,823	0	—	—	—
Other current liability	2,306	0	—	—	—
Total current liabilities	5	2	—	—	—
Total liabilities	5	2	1	4	2
Commitments and contingencies (NOTE 6)	—	—	—	—	—
Common stock of $0.0001 par value; 100,000,000 shares authorized; 531,968 and 8,006 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	53	1	49	225	181
Additional paid-in capital	100	83	82	74	71
Accumulated deficit	−94	−82	−76	−64	−32
Total stockholders' equity	6	2	5	10	39
Total liabilities, and stockholders' equity	11	3	7	15	41

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation, amortization and impairment	7,151	4,424	10,051	6,677	19,183
Equity-based compensation	219,058	273,730	524,838	796,803	559,044
Change in fair value of warrant liability	−6,540	0	—	—	—
In-process research and development expense	9	0	0	2	—
Prepaid expenses and other current assets	419,628	492,471	807,770	202,538	−70,470
Accounts payable	−1	334,141	−2	1	−310,660
Accrued expenses	−298,903	−54,326	−1	854,527	170,131
Net cash used in operating activities	−5	−5	−13	−18	−10
Issuance of promissory loan in connection with asset acquisition	−577,000	0	—	—	—
Cash received from asset acquisition, net of cash paid	1	0	—	—	—
Net cash provided by investing activities	764,735	0	0	−2	0
Proceeds from issuance of equity securities, net	13	2	7	2	27
Payments on note payable	−221,866	−466,505	−280,917	0	−477,028
Net cash provided by financing activities	12	1	7	2	28
Net increase (decrease) in cash, cash equivalents , and restricted cash	8	−3	−6	−17	18
Cash paid for interest	5,800	10,643	14,754	0	1,468
Preferred stock issued for in-process research and development technology	4	0	—	487,900	0
Accrued issuance costs for public offering	185,032	0	—	—	—
Settlement of promissory loans in connection with asset acquisition	577,000	0	—	—	—
Prepaid expense financed by note payable	0	398,728	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro